^
Association details:
| Biomarker: | BRCA2 L557* |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
Published date:
12/01/2020
Excerpt:
Here, we report a 60-year-old Chinese woman...Among them, the germline BRCA2 c.1670T>A mutation was discovered for the first time...These observations suggested that Olaparib treatment successfully controlled the tumor development...In conclusion, our study reported for the first time that UC patients with BRCA2 pathogenic germline mutations responded well to PARPi, indicating that Olaparib can be used in the treatment of UC...
